Renovacor, Inc.

Chardan NexTech Acquisition 2 Corp. (Nasdaq: CHAQ), sponsored by Chardan Capital Markets, completed its initial public offering in 2021 with a focus on the healthcare and life sciences sector. The blank-check company entered into a definitive merger agreement with Renovacor, Inc., a clinical-stage gene therapy company developing treatments for heart failure associated with mutations in the BAG3 gene. The company filed an 8-K with the SEC on May 26, 2022 in connection with developments related to that proposed business combination. For full filing histories, deal timelines, and sponsor data on CHAQ and hundreds of other SPACs, sign up for access at SpacDesk.